Yu Shen

Peer-Reviewed Articles

1. Wang S, Ning J, Xu Y, Shih YT, Shen Y, Li L. Longitudinal Varying Coefficient Single-index Model with Censored Covariates. Biometrics 80(1), 2024. e-Pub 2024. PMID: 38364803.
2. Li Z, Shen Y, Ning J. Accommodating time-varying heterogeneity in risk estimation under the Cox model: a transfer learning approach. J Am Stat Assoc. e-Pub 2023.
3. Pak D, Ning J, Kryscio RJ, Shen Y. Evaluation of the natural history of disease by combining incident and prevalent cohorts: application to the Nun Study. Lifetime Data Anal:1-17. e-Pub 2023. PMID: 37210470.
4. Wang SK, Shen Y, Shih TYC, Xu Y, Li L. Statistical Modeling of Longitudinal Medical Cost Trajectory: Renal Cell Cancer Care Cost Analyse. Biostistics 24(2):244-261, 2023. PMID: 34269395.
5. Smith-Graziani DJ, Parker PA, Peterson SK, Bedrosian I, Shen Y, Black DM, DeSnyder SM, Hunt KK, Dong W, Brewster AM. Prospective Study of Pain Outcomes Associated with Breast Surgery in Women with Nonhereditary Breast Cancer. Ann Surg 277(3):e617-e623, 2023. e-Pub 2021. PMID: 33938495.
6. Shen Y, Ning J, Lin HY, Shaitelman SF, Kuerer HM, Bedrosian I. Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial. Journal of Cancer 14(2):193-199, 2023.
7. Johnson HM, Lin HY, Shen Y, Diego E, Krishnamurthy S, Yang WT, Smith BD, Valero V, Lucci A, Sun SX, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Rauch GM and Kuerer HM. Longitudinal Patient-Reported Outcomes in a Phase 2 Cancer Clinical Trial of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy. JAMA Network Open 6(9). e-Pub 2023.
8. Long J, Shen Y. Detection Method Has Independent Prognostic Significance in the PLCO Lung Screening Trial. Scientific Reports(13):13382. e-Pub 2023.
9. Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Exceptional Responders Clinical Trials Group. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol 23(12):1517-1524, 2022. e-Pub 2022. PMID: 36306810.
10. Zhu H, Lan Y, Ning J, Shen Y. Semiparametric copula-based regression modeling of semi-competing risks data. Communications in Statistics – Theory and Methods 51(22):7830–7845, 2022.
11. Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. Int J Cancer 150:2025–2037, 2022. e-Pub 2022. PMID: 35133007.
12. Chen Z, Ning J, Shen Y, Qin J. Combining primary cohort data with external aggregate information without assuming comparability. Biometrics 77(3):1024-1036, 2021. e-Pub 2020. PMID: 32827153.
13. Bofill Roig M, Shen Y, Gómez Melis G. Design of phase III trials with long-term survival outcomes based on short-term binary results. Stat Med 40(18):4122-4135, 2021. e-Pub 2021. PMID: 33942352.
14. Boyce-Fappiano D, Bedrosian I,Shen Y, Lin H, Gjyshi O, Yoder A, Shaitelman SF, Woodward WA. Evaluation of Overall Survival and Barriers to Surgery for Patients with Breast Cancer Treated without Surgery: A National Cancer Data Base Analysis. NPJ Breast Cancer 7(1):87, 2021. e-Pub 2021. PMID: 34226566.
15. Tamirisa N, Lin H, Shen Y, Shaitelman SF, Karuturi MS, Giordano SH, Babiera GV, Bedrosian I. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-a National Cancer Database analysis. Cancer 127(13):2196-2203, 2021. e-Pub 2021. PMID: 33735487.
16. Yang L, Roy M, Lin H, Shen Y, Abarracin C, Huo L, Chen H, Wei B, Bedrosian I, Bu H, Wu Y. Validation of Prognostic Significance of the Proposed Uniform Classification Framework in Neuroendocrine Neoplasms of the Breast. Breast Cancer Res Treat 186(2):403-415, 2021. e-Pub 2021. PMID: 33528758.
17. Shih YT, Dong W, Xu Y, Etzioni R, Shen Y. Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer: A Cost-Effectiveness Analysis. Ann Intern Med 174:602-612. e-Pub 2021. PMID: 33556275.
18. Qin J, Deng G, Ning J, Yuan A, Shen Y. Estrogen receptor expression on breast cancer patients' survival under shape restricted Cox regression model. Annals of Applied Statistics 15(3):1291-1307, 2021.
19. Pak D, Liu J, Ning J, Gómez G, Shen Y. Analyzing left-truncated and right-censored infectious disease cohort data with interval-censored infection onset. Stat Med 40(2):287-298, 2021. e-Pub 2020. PMID: 33086432.
20. Etzioni R, Shen Y, Shih YT. Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective. J Natl Cancer Inst. e-Pub 2020. PMID: 33301010.
21. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
22. Tamirisa N, Lin H, Shen Y, Shaitelman SF, Sri Karuturi M, Giordano SH, Babiera G, Bedrosian I. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. JAMA Oncol 6(10):1548--1554, 2020. e-Pub 2020. PMID: 32672820.
23. Pak D, Langohr K, Ning J, Martinez JC, Melis LG, Shen Y. Age Associated Coronavirus Disease 2019 Incubation Period: Impact on Quarantine Policy. MDPI: Mathematics 8(9), 2020. e-Pub 2020.
24. Lee CH, Zhou H, Ning J, Liu DD, Shen Y. CoxPhLb: An R Package for Analyzing Length-Biased Data under Cox Model. R Journal 12(1):118-130, 2020. PMID: 33133648.
25. Shih YT, Shen Y. Time to Consider a Personalized Approach to Incorporate Tomosynthesis into Routine Breast Cancer Screening. J Natl Cancer Inst 112(6):553-554, 2020. e-Pub 2019. PMID: 31503277.
26. Huang X, Liu L, Ning J, Li L, Shen Y. Estimation of the Distribution of Longitudinal Biomarker Trajectories Prior to Disease Progression. Stat Med 38(11):2030-2046, 2019. e-Pub 2019. PMID: 30614014.
27. Lee CH, Ning J, Kryscio RJ, Shen Y. Analysis of combined incident and prevalent cohort data under a proportional mean residual life model. Stat Med 38(12):2103-2114, 2019. e-Pub 2019. PMID: 30680767.
28. Piao J, Ning J, Shen Y. Semiparametric Model for Bivariate Survival Data Subject to Biased Sampling. J R Stat Soc Ser B 81(2):409-429, 2019. e-Pub 2019. PMID: 31435191.
29. Shen Y, Dong W, Gulati R, Ryser MD, Etzioni R. Estimating the frequency of indolent breast cancer in screening trials. Stat Methods Med Res 28(4):1261-1271, 2019. e-Pub 2018. PMID: 29402176.
30. Tina Shih YC, Dong W, Xu Y, Shen Y. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women from the American Cancer Society and US Preventive Services Task Force. Value Health 22(2):185-193, 2019. e-Pub 2018. PMID: 30711063.
31. Lee CH, Ning J, Shen Y. Model diagnostics for the proportional hazards model with length-biased data. Lifetime Data Anal 25:79-96, 2019. e-Pub 2018. PMID: 29450809.
32. Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: A network meta-analysis. Breast Cancer Res Treat 173(1):1-9, 2019. e-Pub 2018. PMID: 30242579.
33. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ and Margins <2mm: Contemporary Outcomes With Breast Conservation. Ann Surg 269:150-157, 2019. e-Pub 2017. PMID: 28742682.
34. Ryser MD, Gulati R, Eisenberg MC, Shen Y, Hwang ES, Etzioni RB. Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. Am J Epidemiol 188(1):197-205, 2019. e-Pub 2018. PMID: 30325415.
35. Mao H, Li L, Yang W, Shen Y. On the propensity score weighting analysis with survival outcome: estimands, estimation and inference. Stat Med 37(26):3745-63, 2018. e-Pub 2018. PMID: 29855060.
36. Weiss A, Chu CK, Lin H, Shen Y, Shaitelman SF, Garvey PB, Bedrosian I, Babiera GV. Reconstruction in the Metastatic Breast Cancer Patient - Results from the National Cancer Database. Ann Surg Oncol 25(11):3125-33, 2018. e-Pub 2018. PMID: 30109538.
37. Shaitelman SF, Lei X, Thompson A, Schlembach P, Bloom ES, Arzu IY, Buchholz D, Chronowski G, Dvorak T, Grade E, Hoffman K, Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Amaya DN, Shen Y, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD. Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. J Clin Oncol 36(35):3495-3503. e-Pub 2018. PMID: 30379626.
38. Parker PA, Peterson SK, Shen Y, Bedrosian I, Black DM, Thompson AM, Nelson JC, DeSnyder SM, Cook RL, Hunt KK, Volk RJ, Cantor SB, Dong W, Brewster AM. Prospective study of psychosocial outcomes of having contralateral prophylactic mastectomy among women with non-hereditary breast cancer. J Clin Oncol 36(25):2630-2638, 2018. e-Pub 2018. PMID: 30044695.
39. Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol 4(9):1207-1213, 2018. e-Pub 2018. PMID: 29879283.
40. Lee CH, Ning J, Shen Y. Analysis of Restricted Mean Survival Time for Length-Biased Data. Biometrics 74(2):575-583, 2018. e-Pub 2017. PMID: 28886217.
41. Li L, Wu CH, Ning J, Huang X, Tina Shih YC, Shen Y. Semiparametric Estimation of Longitudinal Medical Cost Trajectory. J Am Stat Assoc 113(522):582-592, 2018. e-Pub 2018. PMID: 30853736.
42. Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 28(10):2420-2428, 2017. PMID: 28961844.
43. Tadros A, Lin H, MacGregor M, Bedrosian I, Shen Y, Yi M, Giordano SH, Hunt KK, Mittendorf EA. Validation of a Risk Score to Enhance Prognostic Stratification of Breast Cancer Patients Using the National Cancer Data Base (NCDB). Journal of the American College of Surgeons 225(4):S26, 2017.
44. Moreno AC, Lin YH, Bedrosian I, Shen Y, Stauder MC, Smith BD, Buchholz TA, Babiera GV, Woodward WA, Shaitelman SF. Use of Regional Nodal Irradiation and its Association with Survival for Women with High-Risk, Early-Stage Breast Cancer: A National Cancer Data Base Analysis. Adv Radiat Oncol 2(3):291-300, 2017. e-Pub 2017. PMID: 29114595.
45. Lin HY, Bedrosian I, Babiera GV, Shaitelman SF, Kuerer HM, Woodward WA, Ueno NT, Shen Y. Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer 123(14):2618-2625, 2017. e-Pub 2017. PMID: 28295213.
46. Ning J, Hong C, Li L, Huang X, Shen Y. Estimating Treatment Effects in Observational Studies with Both Prevalent and Incident Cohorts. Can J Stat 45(2):202-219, 2017. e-Pub 2017. PMID: 29056817.
47. Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH. Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123(11):1935-1940, 2017. e-Pub 2017. PMID: 28135395.
48. Liu H, Shen Y, Ning J, Qin J. Sample size calculations for prevalent cohort designs. Stat Methods Med Res 26(1):280-291, 2017. e-Pub 2016. PMID: 25091809.
49. Shen Y, Ning J, Qin J. Nonparametric and Semiparametric Regression Estimation for Length-biased Survival Data. Lifetime Data Anal 23(1):3-24, 2017. e-Pub 2016. PMID: 27086362.
50. Zhu H, Ning J, Shen Y, Qin J. Semiparametric density ratio modeling of survival data from a prevalent cohort. Biostatistics 18(1):62-75, 2017. e-Pub 2016. PMID: 27354710.
51. Liu H, Ning J, Qin J and Shen Y. Semiparametric Maximum Likelihood Inference for Truncated or Biased-Sampling Data. Stat Sinica 26(3):1087-1115, 2016.
52. Loveland-Jones C, Lin H, Shen Y, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno N, Valero V, Babiera G. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys 95(4):1218-25, 2016. e-Pub 2016. PMID: 27209502.
53. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol 69(5):855-862, 2016. e-Pub 2015. PMID: 26343003.
54. Parker PA, Peterson SK, Bedrosian I, Crosby MA, Shen Y, Black DM, Babiera G, Kuerer HM, Ying J, Dong W, Cantor SB, Brewster AM. Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer. Ann Surg 263(1):178-83, 2016. PMID: 25822675.
55. Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol 1(9):1311-8, 2015. e-Pub 2015. PMID: 26402167.
56. Ning J, Peng S, Ueno N, Xu Y, Shih Y, Karuturi M, Giordano S, Shen Y. Has Racial Difference in Cause-Specific Death Improved in Older Patients with Late-Stage Breast Cancer?. Ann Oncol 26(10):2161-8, 2015. e-Pub 2015. PMID: 26223248.
57. Lautner M, Lin H, Shen Y, Parker C, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Disparities in the Use of Breast-Conserving Therapy Among Patients With Early-Stage Breast Cancer. JAMA Surg 150(8):778-86, 2015. e-Pub 2015. PMID: 26083835.
58. Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y. Cost-Effectiveness of Alternative Strategies for Integrating MRI into Breast Cancer Screening for Women at High Risk. Br J Cancer 111(8):1542-51, 2014. e-Pub 2014. PMID: 25137022.
59. Ning J, Qin J, Shen Y. Score Estimating Equations from Embedded Likelihood Functions under Accelerated Failure Time Model. J Am Stat Assoc 109(508):1625-35, 2014. PMID: 25663727.
60. Hoffman KE, Niu J, Shen Y, Jiang J, Davis JW, Kim J, Kuban DA, Perkins GH, Shah JB, Smith GL, Volk RJ, Buchholz TA, Giordano SH, Smith BD. Physician Variation in Management of Low-Risk Prostate Cancer: a Population-based Cohort Study. JAMA Intern Med 174(9):1450-9, 2014. PMID: 25023650.
61. Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the national cancer database. J Clin Oncol 32(19):2018-24, 2014. e-Pub 2014. PMID: 24888808.
62. Eberth JM, Xu Y, Smith GL, Shen Y, Jiang J, Buchholz TA, Hunt KK, Black DM, Giordano SH, Whitman GJ, Yang W, Shen C, Elting L, Smith BD. Surgeon influence on use of needle biopsy in patients with breast cancer: a national medicare study. J Clin Oncol 32(21):2206-16, 2014. e-Pub 2014. PMID: 24912900.
63. Shih YC, Xu Y, Dong W, Smieliauskas F, Giordano S, Shen Y. First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer. Breast Cancer Res Treat 144(2):417-25, 2014. e-Pub 2014. PMID: 24557339.
64. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25(2):384-391, 2014. e-Pub 2013. PMID: 24351399.
65. Ning J, Qin J, Shen Y. Semiparametric accelerated failure time model for length-biased data with application to dementia study. Stat Sin 24(1):313-333, 2014. PMID: 24478570.
66. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T-cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1(4):229-34, 2013. e-Pub 2013. PMID: 24777852.
67. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic down-staging and long-term outcomes. Results from a retrospective study at the M. D. Anderson Cancer Center. Eur Urol 64(2):307-13, 2013. e-Pub 2012. PMID: 22564397.
68. Ning J, Qin J, Asgharian M, Shen Y. Empirical likelihood-based confidence intervals for length-biased data. Stat Med 32(13):2278-2291, 2013. e-Pub 2012. PMID: 23027662.
69. Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: Final results. Cancer 119(3):540-547, 2013. e-Pub 2012. PMID: 22914978.
70. Cheng Y, Shen Y. An efficient sequential design of clinical trials. J Stat Plan Inference 143(2):283-295, 2013. PMID: 23275685.
71. Brewster AM, Bedrosian I, Parker PA, Dong W, Peterson SK, Cantor SB, Crosby M, Shen Y. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118(22):5637-43, 2012. e-Pub 2012. PMID: 22517269.
72. Albert JM, Liu DD, Shen Y, Pan IW, Shih YC, Hoffman KE, Buchholz TA, Giordano SH, Smith BD. Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol 30(23):2837-43, 2012. e-Pub 2012. PMID: 22734034.
73. Shen Y, Ning J, Qin J. Likelihood approaches for invariant density ratio model with biased-sampling data. Biometrika 99(2):363-378, 2012. e-Pub 2012. PMID: 23843663.
74. Ning J, Qin J, Shen Y. Buckley-James type Estimator with Right-censored and Length-biased Data. Biometrics 67(4):1369-78, 2011. e-Pub 2011. PMID: 21385160.
75. Qin J, Ning J, Liu H, Shen Y. Maximum likelihood estimations and EM algorithms with length-biased data. J Am Stat Assoc 106(496):1434-49, 2011. PMID: 22323840.
76. Ahern CH, Cheng Y, Shen Y. Risk-specific optimal cancer screening schedules: an application to breast cancer early detection. Stat Biosci 3(2):169-186, 2011. PMID: 22162743.
77. Ning J, Qin J, Shen Y. Nonparametric tests for right-censored data with biased sampling. J R Stat Soc Ser B 72(5):609-630, 2010. PMID: 21031144.
78. Qin J, Shen Y. Statistical Methods for Analyzing Right-censored Length-biased Data under Cox Model. Biometrics 66(2):382-392, 2010. e-Pub 2009. PMID: 19522872.
79. Liu H, Shen Y. A Semiparametric Regression Cure Model for Interval-Censored Data. J Am Stat Assoc 104(487):1168-1178, 2009. PMID: 20354594.
80. Shen Y, Ning J, Qin J. Analyzing Length-biased Data with Semiparametric Transformation and Accelerated Failure Time Models. J Am Stat Assoc 104(487):1192-1202, 2009. PMID: 21057599.
81. Ahern CH, Shen Y. Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines. Cancer Epidemiol Biomarkers Prev 18(3):718-725, 2009. e-Pub 2009. PMID: 19258473.
82. Shen Y, Dong W, Feig BW, Ravdin P, Theriault RL, Giordano SH. Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer 115(10):2041-2051, 2009. e-Pub 2009. PMID: 19288569.
83. Shen Y, Costantino JP, Qin J. Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. J Natl Cancer Inst 100(20):1448-53, 2008. e-Pub 2008. PMID: 18840821.
84. Bekele BN, Ji Y, Shen Y, Thall PF. Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics 9(3):442-57, 2008. e-Pub 2007. PMID: 18084008.
85. Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 17(5):1096-103, 2008. PMID: 18483331.
86. Shen Y, Qin J, Costantino JP. Inference of Tamoxifen's Effects on Prevention of Breast Cancer from a Randomized Controlled Trial. J Am Stat Assoc 102(480):1235-1244, 2007. PMID: 19662105.
87. Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, Giles F, Kantarjian H. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma 48(6):1150-60, 2007. PMID: 17577778.
88. Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?. Breast Cancer Res Treat 102(3):347-356, 2007. e-Pub 2006. PMID: 17028980.
89. Shen Y, Cheng Y. Adaptive Design: Estimation and Inference with Censored Data in a Semiparametric Model. Biostatistics 8:306-322, 2007. PMID: 16787996.
90. Cong XJ, Yin G, Shen Y. Marginal Analysis of Correlated Failure Time Data with Informative Cluster Sizes. Biometrics 63(3):663-672, 2007. PMID: 17825000.
91. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104(10):3967-72, 2007. PMID: 17360461.
92. Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma 47(3):417-23, 2006. PMID: 16396764.
93. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295:299-305, 2006. PMID: 16418465.
94. Zeng D, Cai J, Shen Y. Semiparameteric additive risks model for interval-censored data. Statistica Sinica 16:287-95, 2006. PMID: NIPM.
95. Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. Modeling the Impact of Treatment and Screening on U.S. Breast Cancer Mortality: A Bayesian Approach. J Natl Cancer Inst Monogr 36(36):30-6, 2006. PMID: 17032892.
96. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12:5442-7, 2006. PMID: 17000678.
97. Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial. Biometrics 61(4):992-9, 2005. PMID: 16401272.
98. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784-92, 2005. PMID: 16251534.
99. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97(16):1195-203, 2005. PMID: 16106024.
100. Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics 6:604-14, 2005. PMID: 15860542.
101. Shen Y, Parmigiani G. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations. Cancer Epidemiol Biomarkers Prev 14:529-32, 2005. PMID: 15734983.
102. Cong XJ, Shen Y, Miller AB. Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies. Stat Med 24:3123-38, 2005. PMID: 15977269.
103. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7):810-6, 2005. PMID: 15713770.
104. Bekele BN, Shen Y. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics 61(2):343-54, 2005. PMID: 16011680.
105. Cheng Y, Shen Y. Bayesian Adaptive Designs for Clinical Trials. Biometrika 92:633-646, 2005. PMID: Not in PubMed.
106. Yin G, Shen Y. Adaptive design and estimation in randomized clinical trials with correlated observations. Biometrics 61:362-9, 2005. PMID: 16011682.
107. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10:33-42, 2004. PMID: 14734449.
108. Cheng Y, Shen Y. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials. Biometrics 60:910-8, 2004. PMID: 15606411.
109. Shen Y, Cai J. Sample size re-estimate for clinical trials with censored survival data. J Am Stat Assoc 98:418-426, 2003.
110. Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian HM, Rogers A, Jilani I, Lin CW, Pierce S, Freireich EJ, Estey EH. Myelodysplastic syndrome is not merely "preleukemia". Blood 100(3):791-8, 2002. PMID: 12130488.
111. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-60, 2002. PMID: 12010890.
112. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JP. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 94:755-61, 2002. PMID: 12011226.
113. Shen Y, Wu D, Zelen M. Testing the independence of two diagnostic tests. Biometrics 57:1009-17, 2001. PMID: 11764239.
114. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol 19:3490-9, 2001. PMID: 11481355.
115. Van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC, Jr, Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92:2837-44, 2001. PMID: 11753957.
116. Shen Y, Cai J. Maximum of the weighted Kaplan-Meier tests with application to cancer prevention and screening trials. Biometrics 57:837-43, 2001. PMID: 11550935.
117. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood 95:72-7, 2000. PMID: 10607687.
118. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-52, 2000. PMID: 10874062.
119. Thall PF, Simon RM, Shen Y. Approximate Bayesian evaluation of multiple treatment effects. Biometrics 56:213-9, 2000. PMID: 10783798.
120. Shen Y, Fisher L. Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics 55:190-7, 1999. PMID: 11318154.
121. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 117:350-8, 1999. PMID: 10419916.
122. Shen Y, Zelen M. Estimation procedures for screening programs: Stable and nonstable disease models for multi-modality case finding. Biometrika 86:503-515, 1999.
123. Shen Y, Cheng SC. Confidence bands for cumulative incidence curves under the additive risk model. Biometrics 55:1093-100, 1999. PMID: 11315053.
124. Shen Y, Fleming TR. Assessing effects on long-term survival after early termination of randomized trials. Lifetime Data Anal 5:55-66, 1999. PMID: 10214002.
125. Shen Y, Thall PF. Parametric likelihoods for multiple non-fatal competing risks and death. Stat Med 17:999-1015, 1998. PMID: 9612887.
126. Shen Y, Fleming TR. Weighted mean survival test statistics: a class of distance tests for censored survival data. J R Stat Soc Ser B 59:269-280, 1997.
127. Shen Y, Fleming TR. Large sample properties for some survival estimators in heterogeneous samples. J Stat Plan Inference 60:123-138, 1997.
128. Etzioni R, Shen Y. Estimating asymptomatic duration in cancer: the AIDS connection. Stat Med 16:627-44, 1997. PMID: 9131752.
129. Sinicrope FA, Roddey G, McDonnell TJ, Shen Y, Cleary KR, Stephens LC. Increased apoptosis accompanies neoplastic development in the human colorectum. Clin Cancer Res 2:1999-2006, 1996. PMID: 9816159.
130. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Research 56:3870-4, 1996. PMID: 8752148.